Table 3.
Treatment completion rate for MDR-TB contacts by age and regimen, Chuuk, Federated States of Micronesia, 2009–2012
| Patients who started treatment n |
Patients who completed treatment n (%) |
|
|---|---|---|
| Age, years | ||
| <5 | 6 | 6 (100) |
| 5–11 | 20 | 19 (95) |
| 12–17 | 17 | 17 (100) |
| 18–25 | 17 | 14 (82) |
| 26–40 | 14 | 11 (73) |
| 41–55 | 17 | 15 (88) |
| >55 | 13 | 11 (85) |
| Total | 104 | 93 (89) |
| Treatment regimen | ||
| MFX only | 46 | 36 (83) |
| MFX + EMB | 24 | 21 (88) |
| LVX only* | 5 | 5 (100) |
| LVX + EMB | 17 | 16 (94) |
| LVX + ETH | 12 | 12 (100) |
| Total | 104 | 93 (89) |
*
Four patients who began treatment with MFX alone received <6 months of MFX before completing the remainder of treatment with LVX only. These four patients are included in the LVX only group.
MDR-TB = multidrug-resistant tuberculosis; MFX = moxifloxacin; EMB = ethambutol; LVX = levofloxacin; ETH = ethionamide.